143 related articles for article (PubMed ID: 26852860)
21. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.
Afonso FJ; Anido U; Fernández-Calvo O; Vázquez-Estévez S; León L; Lázaro M; Ramos M; Antón-Aparicio L
Clin Transl Oncol; 2013 Jun; 15(6):425-33. PubMed ID: 23401018
[TBL] [Abstract][Full Text] [Related]
22. Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases.
Procopio G; Verzoni E; Biondani P; Grassi P; Testa I; Garanzini E; de Braud F
Tumori; 2014; 100(1):e28-30. PubMed ID: 24675507
[TBL] [Abstract][Full Text] [Related]
23. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Yuasa T; Urakami S; Yamamoto S; Yonese J; Nakano K; Kodaira M; Takahashi S; Hatake K; Inamura K; Ishikwa Y; Fukui I
Urology; 2011 Apr; 77(4):831-5. PubMed ID: 21316083
[TBL] [Abstract][Full Text] [Related]
24. Case of sorafenib-induced thyroid storm.
Haraldsdottir S; Li Q; Villalona-Calero MA; Olencki TE; Kendra K; Ing SW
J Clin Oncol; 2013 Jun; 31(16):e262-4. PubMed ID: 23610115
[No Abstract] [Full Text] [Related]
25. Third-line dovitinib in metastatic renal cell carcinoma.
Schmidinger M
Lancet Oncol; 2014 Mar; 15(3):245-6. PubMed ID: 24556039
[No Abstract] [Full Text] [Related]
26. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
[TBL] [Abstract][Full Text] [Related]
27. An update on the medical therapy of advanced metastatic renal cell carcinoma.
Kruck S; Merseburger AS; Gakis G; Kramer MW; Stenzl A; Kuczyk MA
Scand J Urol Nephrol; 2008; 42(6):501-6. PubMed ID: 18615363
[TBL] [Abstract][Full Text] [Related]
28. New therapeutic approaches in the management of metastatic renal cell carcinoma.
Gkialas IK; Papadopoulos G
J BUON; 2009; 14(3):399-404. PubMed ID: 19810129
[TBL] [Abstract][Full Text] [Related]
29. Survival trends among patients with advanced renal cell carcinoma in the United States.
Shah BK; Ghimire KB
Urol Int; 2015; 94(2):133-6. PubMed ID: 25138899
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
Tafreshi A; Thientosapol E; Liew MS; Guo Y; Quaggiotto M; Boyer M; Davis ID
Asia Pac J Clin Oncol; 2014 Mar; 10(1):60-5. PubMed ID: 24152417
[TBL] [Abstract][Full Text] [Related]
31. New options for second-line therapy of advanced renal cancer.
Bex A
Lancet Oncol; 2013 May; 14(6):450-1. PubMed ID: 23598169
[No Abstract] [Full Text] [Related]
32. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Mehta A; Sonpavde G; Escudier B
Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
[TBL] [Abstract][Full Text] [Related]
33. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Zhang HL; Zhu Y; Qin XJ; Wang CF; Yao XD; Zhang SL; Dai B; Zhu YP; Shi GH; Ye DW
Clin Genitourin Cancer; 2013 Jun; 11(2):134-40. PubMed ID: 23058498
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
35. Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Zhang P; Xing Z; Li X; Song Y; Zhao J; Xiao Y; Xing Y
Int J Oncol; 2016 Apr; 48(4):1417-25. PubMed ID: 26820170
[TBL] [Abstract][Full Text] [Related]
36. Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Harshman LC; Yu RJ; Allen GI; Srinivas S; Gill HS; Chung BI
Urol Oncol; 2013 Apr; 31(3):379-85. PubMed ID: 21353796
[TBL] [Abstract][Full Text] [Related]
37. Urological cancer: second-line option for metastatic RCC.
Marchesi V
Nat Rev Clin Oncol; 2013 Jun; 10(6):305. PubMed ID: 23629471
[No Abstract] [Full Text] [Related]
38. Recent advances in the systemic treatment of metastatic papillary renal cancer.
Chowdhury S; Choueiri TK
Expert Rev Anticancer Ther; 2009 Mar; 9(3):373-9. PubMed ID: 19275514
[TBL] [Abstract][Full Text] [Related]
39. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
40. Preparation of envelope-type lipid nanoparticles containing gold nanorods for photothermal cancer therapy.
Paraiso WKD; Tanaka H; Sato Y; Shirane D; Suzuki N; Ogra Y; Tange K; Nakai Y; Yoshioka H; Harashima H; Akita H
Colloids Surf B Biointerfaces; 2017 Dec; 160():715-723. PubMed ID: 29035819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
